EU/3/11/925

About

On 27 October 2011, orphan designation (EU/3/11/925) was granted by the European Commission to Voisin Consulting S.A.R.L., France, for mifepristone for the treatment of hypercortisolism (Cushing's syndrome) of endogenous origin.

The sponsorship was transferred to Dr Ulrich Granzer, Germany, in December 2012 and subsequently to FGK Representative Service GmbH, Germany, in October 2013 and to Dr Ulrich Granzer, Germany, in August 2015.

Key facts

Active substance
mifepristone
Medicine name
Corluxin
Disease / condition
Treatment of hypercortisolism (Cushing's syndrome) of endogenous origin
Date of decision
27/10/2011
Outcome
Positive
Orphan decision number
EU/3/11/925

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Dr Ulrich Granzer
Mauerkircherstrasse 105
81925 Munich
Germany
Tel. +49 8978 0689820
Fax +49 8978 0689815
E-mail: granzer@granzer.biz

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating